April D. Sorrell, Todd A. Alonzo, Joanne M. Hilden, Robert B. Gerbing, Thomas W. Loew, Lois Hathaway, Dorothy Barnard, Jeffrey W. Taub, Yaddanapudi Ravindranath, Franklin O. Smith, Robert J. Arceci, William G. Woods and Alan S. Gamis Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971 Cancer 118
Article first published online: 5 MAR 2012 | DOI: 10.1002/cncr.27484
Children's Oncology Group trial A2971 (COG A2971), the first phase 3 trial designed to uniformly treat myeloid leukemia in North American children with Down syndrome, eliminates 2 induction drugs and 3 months of maintenance from the standard-timing dexamethasone, cytarabine, 6-thioguanine, etoposide, and rubidomycin/daunomycin (DCTER) regimen that was used in Children's Cancer Group trial 2891. COG A2971 reduces the chemotherapy dose and maintains survival in children who have myeloid leukemia associated with Down syndrome.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field